Focus: Vedanta Biosciences is a Cambridge-based biotech company focused on therapies that modulate the microbiome-immune system interaction, with a pipeline concentrated in gastroenterology and infectious disease.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Vedanta Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Vedanta Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vedanta Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences Yahoo Finance
Vedanta Biosciences - thepharmaletter.com
Vedanta Biosciences thepharmaletter.com
Human Microbiome Market - Future Market Insights
Human Microbiome Market Future Market Insights
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit Yahoo Finance
Vedanta secures $60 million ahead of pivotal Phase III C. difficile data - The Pharma Letter
Vedanta secures $60 million ahead of pivotal Phase III C. difficile data The Pharma Letter
Vedanta Biosciences Raises $60 Million To Advance Phase 3 VE303 Study - Pulse 2.0
Vedanta Biosciences Raises $60 Million To Advance Phase 3 VE303 Study Pulse 2.0
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults.
Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo